KZIA - KAZIA THERAPEUTICS LTD
1.4
-0.070 -5.000%
Share volume: 275,373
Last Updated: Tue 04 Feb 2025 10:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.37%
PREVIOUS CLOSE
CHG
CHG%
$1.47
-0.09
-0.06%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-11.39%
1 Month
-22.22%
3 Months
-77.16%
6 Months
337.09%
1 Year
418.52%
2 Year
38.61%
Key data
Stock price
$1.40
DAY RANGE
$1.39 - $1.48
52 WEEK RANGE
$0.19 - $7.81
52 WEEK CHANGE
$429.90
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: James S. Garner
Region: US
Website: kaziatherapeutics.com
Employees: 12
IPO year: 1999
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: kaziatherapeutics.com
Employees: 12
IPO year: 1999
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Kazia Therapeutics Limited is an oncology-focused biotechnology company. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway. It is also developing EVT801, an investigational new drug for various forms of cancer.
Recent news